Breaking News Instant updates and real-time market news.

CDK

CDK Global

$71.62

0.81 (1.14%)

, CG

Carlyle Group

$23.65

0.2 (0.85%)

08:52
02/15/18
02/15
08:52
02/15/18
08:52

Carlyle, Silver Lake no longer actively bidding for CDK, Dealreporter says

The valuation of CDK Global (CDK) is giving Carlyle Group (CG) and Silver Lake pause and the private equity consortium is no longer actively working on a CDK buyout, two sources told Dealreporter, according to contacts. If CDK revises its valuation expectations it is possible deal talks could be revived, the report added, according to contacts. Two other PE consortiums - Vista Equity Partners and Bain Capital and Thoma Bravo and Advent International - were no longer actively negotiating with CDK, Bloomberg has said and a source has corroborated to Dealreporter, according to its report.

CDK

CDK Global

$71.62

0.81 (1.14%)

CG

Carlyle Group

$23.65

0.2 (0.85%)

CDK CDK Global
$71.62

0.81 (1.14%)

10/31/17
BRRR
10/31/17
NO CHANGE
BRRR
CDK Global estimates raised after solid Q1 results at Barrington
Barrington analyst Gary Prestopino maintained an Outperform rating and $75 price target on CDK Global, and raised his FY18 adjusted EPS estimate to $2.95 from $2.90 following CDK Global's better than expected Q1 results, with Prestopino saying that CDK "continues to solidly execute on its transformation plan."
01/17/18
BRRR
01/17/18
DOWNGRADE
Target $75
BRRR
Market Perform
CDK Global downgraded to Market Perform from Outperform at Barrington
Barrington analyst Gary Prestopino downgraded CDK Global to Market Perform with an unchanged price target of $75.
01/17/18
BRRR
01/17/18
DOWNGRADE
Target $75
BRRR
Market Perform
CDK Global downgraded to Market Perform on valuation at Barrington
Barrington analyst Gary Prestopino downgraded CDK Global to Market Perform from Outperform citing valuation following the stock's recent rally. A financial buyer may not pay much more of a premium for the company, Prestopino tells investors in a research note, referencing media reports indicating CDK is exploring a sale. The analyst keeps a $75 price target for the shares.
01/31/18
WELS
01/31/18
NO CHANGE
Target $80
WELS
Outperform
CDK Global price target raised to $80 from $75 at Wells Fargo
Wells Fargo analyst Timothy Willi raised his price target for CDK Global to $80 from $75 following quarterly results. The analyst reiterates an Outperform rating on the shares.
CG Carlyle Group
$23.65

0.2 (0.85%)

11/14/17
OPCO
11/14/17
NO CHANGE
Target $40
OPCO
Outperform
Envision buyout price could approach $50 per share, says Oppenheimer
After Bloomberg reported that private equity firms Carlyle Group (CG) and Onex have shown interest, Oppenheimer analyst Michael Wiederhorn says he believes a buyout offer for Envision Healthcare could approach $50 per share. The stock in afternoon trading is up 8% to $27.96. Such an offer is based on an 11 times 2018 EBITDA estimate, which is multiple similar to the one paid by Blackstone (BX) for Team Health in late 2016, Wiederhorn tells investors in a research note. The analyst believes Envision has a "strong growth business" and he recommends continuing to buy the shares at current levels. Wiederhorn has an Outperform rating on Envision with a $40 price target.
12/04/17
MSCO
12/04/17
NO CHANGE
Target $28
MSCO
Overweight
Carlyle Group recent weakness a buying opportunity, says Morgan Stanley
Morgan Stanley analyst Michael Cyprys noted Carlyle Group shares have sold off by over 15% since the announcement of the company's management transition. However, he sees this pullback as a buying opportunity, as he has increased conviction in the company's ability to ramp up management fees in 2018 following a recent Bloomberg article that said its flagship North America buyout fund is approaching a cap of $18.5B, which tops the initial $15B target and would give the company $30B of global corporate private equity buying power when combined with Carlyle's Europe and Asia buyout funds. He maintains an Overweight rating and $28 price target on Carlyle shares.
01/30/18
MSCO
01/30/18
NO CHANGE
MSCO
Morgan Stanley says Ares may be first, Apollo may gain most from C-corp convert
Morgan Stanley analyst Michael Cyprys said he sees an opportunity for Alternative Asset Managers to unlock value by converting to C-corps, as shifting from a partnership structure could help alleviate some tax reporting complexities and expand the universe of eligible investors. He sees Ares Management (ARES) as possibly the first to convert and expects a potential announcement or indications of management's intentions about a conversion when the company reports earnings on February 15. While Ares may be first, Cyprys sees Apollo Global (APO) as potentially being able to unlock the most value from a conversion, with 26% near-term upside possible if the shares re-rate. He sees a less favorable conversion scenario for asset managers with lower taxes and/or greater exposure to performance fees, including KKR (KKR), Carlyle Group (CG) and Blackstone (BX), Cyprys tells investors.
02/14/18
JEFF
02/14/18
UPGRADE
Target $27
JEFF
Buy
Carlyle Group upgraded to Buy from Hold at Jefferies
Jefferies analyst Gerald E. O'Hara upgraded Carlyle Group to Buy and raised his price target for the shares to $27 from $23. The analyst sees an attractive entry point for the shares with the company at the midway point of a $100B fundraising cycle. He believes Carlyle's net accrued performance fees are poised for continued growth with all main drawdown funds currently in carry contribution.

TODAY'S FREE FLY STORIES

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:35
03/25/19
03/25
09:35
03/25/19
09:35
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Downgrade
Texas Instruments rating change  »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
Lantheus promotes John Bolla to COO »

Lantheus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

MEOH

Methanex

$57.73

-2.64 (-4.37%)

09:33
03/25/19
03/25
09:33
03/25/19
09:33
Hot Stocks
M&G Investments announces four director nominees for Methanex board »

M&G Investments, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$41.28

0.75 (1.85%)

09:32
03/25/19
03/25
09:32
03/25/19
09:32
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton benefiting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LNTH

Lantheus

$23.61

-1.575 (-6.25%)

09:31
03/25/19
03/25
09:31
03/25/19
09:31
Hot Stocks
Lantheus announces upcoming retirement of Chief Medical Officer in September »

Lantheus Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

NEON

Neonode

$2.80

(0.00%)

09:28
03/25/19
03/25
09:28
03/25/19
09:28
Hot Stocks
Neonode says Convergence Promotions to act as sales and marketing partner »

Neonode announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.54

-0.525 (-8.66%)

09:27
03/25/19
03/25
09:27
03/25/19
09:27
Syndicate
Breaking Syndicate news story on PLx Pharma »

PLx Pharma files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEX

Wex

$184.59

-6.555 (-3.43%)

09:26
03/25/19
03/25
09:26
03/25/19
09:26
Hot Stocks
Wex to acquire fuel card business of EG Group »

WEX announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$55.29

-2.07 (-3.61%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
Integra LifeSciences participates in a conference call with JPMorgan »

Medical Supplies &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

, VRTX

Vertex

$181.49

-1.07 (-0.59%)

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Recommendations
Proteostasis, Vertex analyst commentary  »

Piper sees 'clear…

PTI

Proteostasis

$4.17

-0.14 (-3.25%)

VRTX

Vertex

$181.49

-1.07 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 10

    Apr

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
General news
A Spring Rebound for Producer Sentiment »

A Spring Rebound for…

09:25
03/25/19
03/25
09:25
03/25/19
09:25
Conference/Events
The U.S. Commodity Futures Trading Commission to hold a meeting »

Open Commission Meeting…

ORGS

Orgenesis

$5.01

-0.19 (-3.65%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Hot Stocks
Orgenesis to establish new facility for cell, gene therapy manufacturing »

Orgenesis announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$3.06

0.28 (10.07%)

09:24
03/25/19
03/25
09:24
03/25/19
09:24
Recommendations
Avon Products analyst commentary at DA Davidson »

Avon Products buyout…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSL

MidSouth Bancorp

$10.22

-0.49 (-4.58%)

09:23
03/25/19
03/25
09:23
03/25/19
09:23
Upgrade
MidSouth Bancorp rating change  »

Sandler O'Neill says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Conference/Events
JPMorgan retail analyst to hold an analyst/industry conference call »

Broadlines &…

PLAN

Anaplan

$38.98

-1.47 (-3.63%)

09:21
03/25/19
03/25
09:21
03/25/19
09:21
Initiation
Anaplan initiated  »

Anaplan initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDOR

Condor Hospitality Trust

$8.70

(0.00%)

09:19
03/25/19
03/25
09:19
03/25/19
09:19
Hot Stocks
Condor Hospitality Trust announces sale of non-core legacy hotel »

Condor Hospitality Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
03/25/19
03/25
09:18
03/25/19
09:18
Options
Overnight activity included 349 trades in SPX and 231 trades in VIX »

349 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTDR

Frontdoor

$32.78

0.38 (1.17%)

09:16
03/25/19
03/25
09:16
03/25/19
09:16
Initiation
Frontdoor initiated  »

Frontdoor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$79.94

-1.29 (-1.59%)

09:15
03/25/19
03/25
09:15
03/25/19
09:15
Downgrade
AbbVie rating change  »

AbbVie downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

09:15
03/25/19
03/25
09:15
03/25/19
09:15
General news
Treasury Action: bond and equity funds have been diverging this month »

Treasury Action: bond and…

09:13
03/25/19
03/25
09:13
03/25/19
09:13
Conference/Events
FTC to hold a meeting »

The Competition &…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.